SI 101
Alternative Names: SI-101; SIRPant-MLatest Information Update: 27 Dec 2023
At a glance
- Originator SIRPant Immunotherapeutics
- Class Antineoplastics; Cell therapies; Immunotherapies; Tumour-agnostic therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
- Preclinical Head and neck cancer; Solid tumours
Most Recent Events
- 14 Dec 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (Intratumoural) (NCT05967416)
- 14 Dec 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in USA (Intratumoural) (NCT05967416)
- 15 Nov 2023 SI 101 receives Orphan Drug status for T-cell lymphoma in USA